EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Clinical Characterization of Enzyme and Transporter Precipitants to Evaluate Drug–Drug Interactions for Orforglipron, a Small Molecule Glucagon‐Like Peptide‐1 Receptor Agonist

Bridget L Morse iD, David E Coutant iD, Xiaosu Ma iD, Sohini Raha, Keerthan Aithal, Clare Nicoll, Luc R A Rougée, Shobha Bhattachar iD

Clinical Pharmacology & Therapeutics · 2026-10 · 120 (4) · 979-990

DOI: 10.1002/cpt.70377 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 03.07.2026. Verfasst von Bridget L Morse und 7 weiteren Autor:innen. Beteiligte Einrichtung: Eli Lilly and Company, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Orforglipron is an orally administered, small‐molecule glucagon‐like peptide‐1 receptor agonist in clinical development for the treatment of type 2 diabetes and obesity. Orforglipron is a substrate of CYP3A4, organic anion transporting polypeptides (OATPs) 1B/1B3, and P‐glycoprotein (P‐gp); however, precipitants commonly used to define these mechanisms have not been fully characterized. The enzyme‐ and transporter‐mediated DDI profile of orforglipron and that of CYP3A4/OATP1B/P‐gp precipitants were characterized in six phase 1 clinical studies in healthy participants. Orforglipron pharmacokinetics were assessed with clarithromycin, carbamazepine, cyclosporine, and quinidine. Precipitant effects on CYP3A and OATP1B activity were measured using midazolam and coproporphyrin‐I (CP‐I). Orforglipron effects on CYP3A, P‐gp, BCRP, and OATP1B were evaluated using midazolam, digoxin, rosuvastatin, simvastatin, atorvastatin, and CP‐I. Mechanistic interrogation of the simvastatin interaction was also conducted. Clarithromycin, carbamazepine, and quinidine had minimal effect on CP‐I pharmacokinetics, while the cyclosporine effect was substantial. Cyclosporine and quinidine weakly increased midazolam exposure. Orforglipron exposure increased in the presence of clarithromycin and cyclosporine and decreased with carbamazepine, demonstrating orforglipron exposure is affected by precipitants of CYP3A4 and OATP1B. Quinidine did not meaningfully change orforglipron exposure. Orforglipron had no clinically meaningful effect on the exposure of midazolam, digoxin, or atorvastatin. A weak increase in rosuvastatin exposure was consistent with BCRP inhibition, as CP‐I data confirmed orforglipron does not affect OATP1B. Increase in simvastatin acid exposure was attributed to the unique disposition of simvastatin rather than enzyme or transporter inhibition. These findings address mechanistic precipitant knowledge gaps and provide a framework for managing potential orforglipron DDIs in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsHumansDrug InteractionsCytochrome P-450 CYP3AClarithromycinLiver-Specific Organic Anion Transporter 1MaleFemaleSolute Carrier Organic Anion Transporter Family Member 1B3QuinidineCoproporphyrinsCarbamazepineCyclosporineATP Binding Cassette Transporter, Subfamily B, Member 1OxadiazolesFluorine Compounds

Substanzen

Cytochrome P-450 CYP3AGlucagon-Like Peptide-1 Receptor AgonistsClarithromycinLiver-Specific Organic Anion Transporter 1CYP3A4 protein, humanSolute Carrier Organic Anion Transporter Family Member 1B3QuinidineSLCO1B1 protein, humanCoproporphyrinsCarbamazepine

Autor:innen und Institutionen

  • Eli Lilly and Company, Indianapolis, Indiana, USA.

ORCID-Profile: Bridget L Morse, David E Coutant, Xiaosu Ma, Shobha Bhattachar

Förderung

  • Eli Lilly and Company

Zitieren

APA

Morse, B. L., Coutant, D. E., Ma, X., Raha, S., Aithal, K., Nicoll, C., Rougée, L. R. A., & Bhattachar, S. (2026). Clinical Characterization of Enzyme and Transporter Precipitants to Evaluate Drug–Drug Interactions for Orforglipron, a Small Molecule Glucagon‐Like Peptide‐1 Receptor Agonist. Clinical Pharmacology & Therapeutics, 120(4), 979-990. https://doi.org/10.1002/cpt.70377

Vancouver

Morse BL, Coutant DE, Ma X, Raha S, Aithal K, Nicoll C, et al. Clinical Characterization of Enzyme and Transporter Precipitants to Evaluate Drug–Drug Interactions for Orforglipron, a Small Molecule Glucagon‐Like Peptide‐1 Receptor Agonist. Clinical Pharmacology & Therapeutics. 2026;120(4):979-990. doi:10.1002/cpt.70377

BibTeX
@article{Morse2026,
  author = {Morse, Bridget L and Coutant, David E and Ma, Xiaosu and Raha, Sohini and Aithal, Keerthan and Nicoll, Clare and Rougée, Luc R A and Bhattachar, Shobha},
  title = {Clinical Characterization of Enzyme and Transporter Precipitants to Evaluate Drug–Drug Interactions for Orforglipron, a Small Molecule Glucagon‐Like Peptide‐1 Receptor Agonist},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2026},
  volume = {120},
  number = {4},
  pages = {979--990},
  doi = {10.1002/cpt.70377}
}
Kostenlos starten →